<DOC>
	<DOCNO>NCT01153490</DOCNO>
	<brief_summary>Cannabis use illicit substance United States . Previous study suggest atypical antipsychotic decrease frequency amount substance use subject without psychotic illness . So far , controlled study assess effectiveness atypical antipsychotic decrease cannabis substance use individual cannabis use disorder . The investigator postulate atypical antipsychotic quetiapine ER effective agent improve substance use outcomes subject cannabis use disorder . In pilot study , investigator test hypothesis heavy cannabis user ( i.e. , individual cannabis dependent smoke three time per week ) . Because 50 % heavy cannabis user report history psychotic experience ( i.e. , attenuate positive symptom ) smoke risk recur psychotic symptom , investigator focus pilot clinical trial subgroup cannabis user order increase risk/benefit ratio study target population may also benefit antipsychotic effect quetiapine ER . Considering lack control study assess efficacy atypical antipsychotic heavy cannabis user , assess effectiveness atypical antipsychotic medication substance use clinical outcome population critical improving prognosis individual . Thus , aim randomize , double-blind , placebo-controlled study ass efficacy atypical antipsychotic ( quetiapine ER ) 120 subject cannabis dependence , recent history ( within year ) attenuate psychotic symptom , use cannabis 3 time per week : ( 1 ) decreasing use cannabis substance ; ( 2 ) prevent recurrence psychotic experience . The investigator also assess effect quetiapine ER crave mood , tolerability . This project 12-week , randomize , double-blind , placebo-controlled study quetiapine ER include comprehensive assessment symptom , substance use , side effect . This study benefit field provide unique data relative efficacy tolerability treatment atypical antipsychotic heavy cannabis user vulnerability psychosis . This study basis future study assess long-term efficacy tolerability atypical antipsychotic individual cannabis use disorder .</brief_summary>
	<brief_title>Improving Substance Use Clinical Outcomes Heavy Cannabis Users With Quetiapine</brief_title>
	<detailed_description />
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>DSMIVdefined diagnosis cannabis dependence ( 304.30 ) assess Structured Clinical Interview Axis I DSMIV Disorders ( SCIDI/P ) ( First 1998 ) ) one attenuate positive symptom score 3 ( 'moderate ' ) , 4 ( 'moderate severe ' ) , 5 ( 'severe psychotic ' ) past year assess Structured Interview Prodromal Syndromes ( SIPS ) Scale Prodromal Symptoms ( SOPS ) ( McGlashan et al , 2001 ) lifetime treatment antipsychotic medication le 2 week cannabis use one year cannabis use three day per week average past 3 month age 18 65 competent willing sign inform consent woman , negative urine pregnancy test agreement use medically accept method birth control study . DSMIV criterion schizophrenia , schizophreniform disorder , schizoaffective disorder , psychotic disorder due general medical condition , psychosis NOS , delusional disorder , brief psychotic disorder , share psychotic disorder , mood disorder ( major depression bipolar ) psychotic feature assess Structured Clinical Interview Axis I DSMIV Disorders ( SCIDI/P ) ( First 1998 ) DSMIV diagnosis psychoactive substance dependence cannabis nicotine environment access cannabis ( e.g. , hospitalization , residential treatment , jail , .. ) one week past three month precede study entry serious neurological endocrine disorder medical condition treatment know affect brain use medication effect monoamine ( e.g. , antidepressant severe medical physical illness criteria National Cholesterol Education Program ( NCEP ) metabolic syndrome ( Expert panel Detection , Evaluation , Treatment High Blood Cholesterol Adults , 2001 ) medical condition require treatment medication psychotropic effect significant risk suicidal homicidal behavior cognitive language limitation , factor would preclude subject provide informed consent participate study procedure treatment medication addiction treatment medication risk addiction ( e.g. , benzodiazepine , barbiturate ) history treatment resistance quetiapine ER medical contraindication quetiapine ER hypersensitivity quetiapine ER component woman , pregnant , breastfeeding , intention become pregnant study timeframe</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Quetiapine</keyword>
	<keyword>Psychotic experience</keyword>
	<keyword>Cannabis dependence</keyword>
	<keyword>Craving</keyword>
	<keyword>Mood</keyword>
	<keyword>Substance use</keyword>
</DOC>